PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

Vancomycin Trough Near 15.9 mg/L Flags Nephrotoxicity Risk

vancomycinpiperacillin-tazobactamglycopeptideacute kidney injurynephrotoxicitytherapeutic drug monitoringtrough concentrationKDIGOretrospective cohortpharmacokinetics Pharmacokinetics / TDM

Background Information

Vancomycin trough over 15.9 mg/L linked to kidney injury.

Vancomycin-associated acute kidney injury (VA-AKI) is a significant safety concern that affects treatment outcomes. VA-AKI occurred in 22.1% of patients; a vancomycin trough concentration of 15.9 mg/L was significantly associated with increased VA-AKI risk. The study suggests using a trough concentration of 15.9 mg/L as a threshold for VA-AKI risk, assisting clinicians when AUC-guided monitoring is unavailable. Vancomycin troughs of 15.9 mg/L may indicate a higher risk for acute kidney injury.

📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.

Authors: Chen S, Zhang Y, Hou X, Wang Y, Zuo C, Huang C, Xia X, Cao C, Lv Q, Li X, Pan K

Citation: Chen S, Zhang Y, Hou X, et al. Risk Stratification for Vancomycin-Associated Acute Kidney Injury in Chinese Adult Inpatients: A Multicenter Retrospective Cohort Study. Infection and drug resistance. 2026;19:618586. doi:10.2147/IDR.S618586

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓
Reviewed by a licensed pharmacist
Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.
Accurate and up-to-date information is our highest priority.
If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.
Thanks for the feedback!
🔒
Deep Analysis: Subscribers Only
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Founding member rate
$8/month. Cancel anytime.

One subscription unlocks this analysis and every other one we publish, plus Practice Signals, PDF reports, and GRADE evidence grades.

Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.
Or $79/year. Founding members keep this rate for as long as they stay subscribed. Cancel anytime from your Account page.